血清miR-210在结直肠癌患者血清中的表达及临床意义

doi:10.6040/j.issn.1671-7554.0.2015.060

摘要/Abstract

摘要： 目的探讨miR-210在结直肠癌(CRC)患者血清中的表达及临床意义。方法通过逆转录实时荧光定量PCR(qRT-PCR)方法,检测48例CRC患者(CRC组)和40例健康体检者(对照组)血清miR-210的表达水平,分析其与临床病理参数的关系。通过检测CRC组中12例患者术前、术后1个月和术后复发时血清中miR-210的表达水平,分析其变化趋势。检测两组CEA和CA199的水平,通过ROC曲线比较miR-210、CEA、CA199对于CRC的诊断效能。结果 CRC组血清miR-210的表达水平高于对照组,并且与肿瘤大小、浸润程度、淋巴结转移、临床分期密切相关(P均<0.05),而与性别、年龄、肿瘤类型及肿瘤分化程度无相关性(P均 > 0.05)。CRC组中12例患者术后1个月血清miR-210的表达较术前降低(P < 0.001),术后复发时血清miR-210的表达较术后1个月升高(P < 0.001)。miR-210诊断CRC的ROC曲线下面积(AUC)为0.835,其诊断效能高于CEA(AUC:0.672, Z=2.230, P < 0.05)和CA199(AUC:0.651, Z=2.427, P < 0.05)。miR-210诊断CRC的特异性为82.5%,敏感性为70.8%,诊断临界值为38.31,阳性预测值为82.9%,阴性预测值为70.2%,准确性为76.1%。结论循环miR-210有望成为早期诊断结直肠癌的新的非侵入性分子标志物。

关键词: 结直肠癌, miR-210, 血清, 分子标志物

Abstract: Objective To explore the expression and clinical significance of miR-210 in serum of patients with colorectal cancer(CRC). Methods The expression levels of miR-210 in serum of 48 CRC patients(CRC group) and 40 healthy people(control group) were tested by quantitative real-time PCR (qRT-PCR), followed by the analysis on the association of miR-210 expression levels with clinicopathological characteristics. The expression levels of miR-210 in serum of 12 patients in CRC group were determined before operation, at one month after operation and recurrence after operation. The expression levels of CA199 and CEA of the two groups were tested. The diagnostic value for CRC was evaluated by comparing the ROC curves of miR-210, CA199 and CEA. Results The expression level of serum miR-210 in CRC group was higher than that in control group, and the expression level of miR-210 in CRC group was associated with tumor size, local invasion, lymph nodes metastasis and clinical TNM stage (all P < 0.05). However, there was no significant correlation between miR-210 expression and gender, age, tumor type and differentiation(all P > 0.05). The expression levels of miR-210 in serum of 12 patients in CRC group at the first month after operation was lower than those before operation(P < 0.001), and its expressions in postoperative recurrence patients of CRC group were higher than that at the first month after operation(P < 0.001). ROC curve analysis showed that AUC for miR-210 was 0.835, which was higher than that of CEA(AUC: 0.672, Z=2.230, P < 0.05) and CA199(AUC: 0.651, Z=2.427, P < 0.05), while the diagnostic specificity, sensitivity, cutoff value, positive predictive value, negative predictive value and accuracy rate of miR-210 were 82.5%, 70.8%, 38.31, 82.9%, 70.2% and 76.1%, respectively. Conclusion Circulating miR-210 might be used as a novel non-invasive biomarker for early diagnosis of CRC.

Key words: Serum, Biomarkers, Colorectal cancer, MiR-210

中图分类号:

R735.3+4

方茜, 曲爱林, 张欣, 杜鲁涛, 杨咏梅, 王传新. 血清miR-210在结直肠癌患者血清中的表达及临床意义[J]. 山东大学学报（医学版）, 2015, 53(6): 77-81.

FANG Qian, QU Ailin, ZHANG Xin, DU Lutao, YANG Yongmei, WANG Chuanxin. Expression and clinical significance of miR-210 in the serum of patients with colorectal cancer[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(6): 77-81.

参考文献

[1] Siegel R, Desantis C, Jemal A. Colorectal cancer statistics[J]. CA Cancer J Clin, 2014, 64(2): 104-117.
[2] Senore C, Ederle A, Fantin A, et al. Acceptability and side-effects of colonoscopy and sigmoidoscopy in a screening setting[J]. J Med Screen, 2011, 18(3):128-134.
[3] Khalid-de Bakker CA, Jonkers DM, Sanduleanu S, et al. Test performance of immunologic fecal occult blood testing and sigmoidoscopy compared with primary colonoscopy screening for colorectal advanced adenomas[J]. Cancer Prev Res (Phila), 2011, 4(10):1563-1571.
[4] Zhang L, Huang J, Yang N, et al. MicroRNAs exhibit high frequency genomic alterations in human cancer[J]. Proc Natl Acad Sci U S A, 2006, 103(24): 9136-9141.
[5] Zeng W, Tu Y, Zhu Y, et al. Predictive power of circulating miRNAs in detecting colorectal cancer[J]. Tumour Biol, 2014 Dec 20.[Epub ahead of print].
[6] Dong Y, Yu J, Ng SS, et al. MicroRNA dysregulation as a prognostic biomarker in colorectal cancer[J]. Cancer Manag Res, 2014, 6: 405-422.
[7] Boisen MK, Dehlendorff C, Linnemann D, et al. Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line capecitabine and oxaliplatin with or without bevacizumab[J]. PLoS One, 2014, 9 (10): e109430. doi: 10.1371/journal.pone.0109430. eCollection 2014.
[8] Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection[J]. Proc Natl Acad Sci U S A, 2008, 105(30): 10513-10518.
[9] Ailin Q, Lutao D,Yongmei Y, et al. Hypoxia-inducible miR-210 is an independent prognostic factor and contributes to metastasis in colorectal cancer[J]. PLoS One, 2014, 9(3): e90952. doi: 10.1371/journal.pone.0090952. eCollection 2014.
[10] 刘慧,杜鲁涛,杨咏梅,等. miR-182在结直肠癌中的表达及其对结直肠癌细胞迁移能力的影响[J].山东大学学报:医学版, 2013, 51(12):70-74. LIU Hui, DU Lutao, YANG Yongmei, et al. Expression of miR-182 in colorectal cancer and its effect on the migration of colorectal cancer cells[J]. Journal of Shandong University(Health Sciences), 2013, 51(12):70-74.
[11] Yang L, Belaguli N, Berger DH. MicroRNA and colorectal cancer[J]. World J Surg, 2009, 33(4):638-646.
[12] Heneghan HM, Miller N, Lowery AJ, et al. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer[J]. Ann Surg, 2010, 251(3):499-505.
[13] Crosby ME, Devlin CM, Glazer PM, et al. Emerging roles of microRNAs in the molecular responses to hypoxia[J]. Curr Pharm Des, 2009, 15(33): 3861-3866.
[14] Huang X, Ding L, Bennewith KL, et al. Hypoxia-inducible miR-210 regulates normoxic gene expression involved in tumor initiation[J]. Mol Cell, 2009, 35(6): 856-867.
[15] McCormick R, Buffa FM, Ragoussis J, et al. The role of hypoxia regulated microRNAs in cancer[J]. Curr Top Microbiol Immunol, 2010, 345:47-70.
[16] Redova M, Poprach A, Besse A, et al. MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cellcarcinoma[J]. Tumour Biol, 2013, 34(1): 481-491.

相关文章 15

[1]	李波波李道堂刘曙光王兴武. 食管癌患者血清中DKK-1的表达[J]. 山东大学学报(医学版), 2209, 47(6): 58-61.
[2]	张辉时庆侯怀水李栋. 人脐带间充质干细胞的无动物血清培养及向肝细胞诱导分化[J]. 山东大学学报(医学版), 2209, 47(6): 88-.
[3]	李宁张征张宏群高希宝. 济南居民膳食硒摄入量与血清硒参考值调查[J]. 山东大学学报(医学版), 2209, 47(6): 121-122.
[4]	张媛李英敏冯月秋常彩云潘华伟王束玫. 血清脂联素水平与肥胖、胰岛素抵抗的关系探讨[J]. 山东大学学报(医学版), 2209, 47(6): 124-.
[5]	李梓绮,魏闫若雪,刘晓晗,刘春铖,赵然,刘玉昆. 长链非编码RNA HEATR3反义RNA 1参与结直肠癌发生发展的功能及其临床意义[J]. 山东大学学报 (医学版), 2025, 63(9): 108-115.
[6]	祝永才,谢艳,齐秋晨,李培龙,王传新,杜鲁涛. 基于外周血单个核细胞ATM基因甲基化的联合模型在胰腺癌早期诊断中的价值[J]. 山东大学学报 (医学版), 2025, 63(6): 78-88.
[7]	杜雪,李春霞,刘云霞,张涛. 基于MFPC-Cox的结直肠癌患者预后动态预测模型[J]. 山东大学学报 (医学版), 2025, 63(5): 101-110.
[8]	王刚,徐鹏演,赵旭安,王海锋,葛苗苗,潘华峰,江志伟. ω-3多不饱和脂肪酸对腹腔镜结直肠癌术后迷走神经和肠功能恢复的影响[J]. 山东大学学报 (医学版), 2025, 63(2): 36-42.
[9]	崔倩倩,李金鹏,吴豫丹,侯志平,孙玮螺,崔盼盼,何培元. 粪便miRNA对结直肠进展期腺瘤无创筛查的临床价值[J]. 山东大学学报 (医学版), 2025, 63(2): 43-50.
[10]	常宇,胡云峰,王会丰,郭静,张跳,郝雅琴,刘雨. 阑尾切除术与结直肠癌发病风险关联的孟德尔随机化研究[J]. 山东大学学报 (医学版), 2025, 63(2): 77-83.
[11]	俞静,王刚,王烨,邵明月,潘华峰,葛苗苗,王海锋,江志伟. 基于I-FEED评分系统观察益气导滞方对结直肠癌术后胃肠功能恢复的影响[J]. 山东大学学报 (医学版), 2025, 63(12): 35-43.
[12]	王潇,孔文茹,崔伟亮,王姝麒. 羊角棉总生物碱增强氟尿嘧啶对结直肠癌化疗敏感性[J]. 山东大学学报 (医学版), 2024, 62(6): 30-37.
[13]	魏闫若雪,李梓绮,刘春铖,刘晓晗,赵然,刘玉昆. 结直肠癌中SP1的瘤内异质性表达及其临床意义[J]. 山东大学学报 (医学版), 2024, 62(5): 89-94.
[14]	刘春铖,刘晓晗,魏闫若雪,李梓绮,刘玉昆,赵然. 结直肠癌中含溴结构域蛋白9的亚细胞定位模式及其临床意义[J]. 山东大学学报 (医学版), 2024, 62(4): 24-30.
[15]	于丽,王弋嘉,杨勇,刘学焕,万雪花,包翠萍,苗蓓亮,李斯琪,李静,刘筠. 基于光学表面波技术探究具核梭杆菌介导的自噬与细胞折射率的关系[J]. 山东大学学报 (医学版), 2024, 62(10): 87-97.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed